Skip to main content
SpringerLink
Log in

Alpha-2-Macroglobulin: Protease Inhibitor Treatment (PRP Variant)

  • Chapter
  • First Online:
Book cover Advanced Procedures for Pain Management

  • 1946 Accesses

Abstract

Alpha-2-macroglobulin (A2M) is a major plasma glycoprotein best known for its ability to inhibit a broad spectrum of inflammatory mediators, such as metalloproteases and inflammatory cytokines by a unique “bait-and-trap” method. A2M has emerged as a unique potential treatment for cartilage-based pathology and inflammatory arthritides. A2M can be concentrated from an autologous source and injected into diseased tissue to enhance healing, prevent further degradation, and protect normal tissue. A2M not only inhibits the associated inflammatory cascade, but also disrupts the catabolic process of cartilage degeneration. Any pathology that is protease-mediated may benefit from A2M therapy.  The half-life is quite long, so successful treatment can result in months of pain relief. Autologous concentrated A2M from plasma is currently used successfully to treat various painful arthritides, including mild to moderate osteoarthritis, post-traumatic osteoarthritis, enthesopathies, and spinal discogenic pain. Recent work has shown that recombinant A2M may be able to enhance cartilage regeneration. The discovery of A2M as the body’s own healing mechanism, with anti-inflammatory and disease-modifying potential, offers great promise.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Bedi A, Kovacevic D, Hettrich C, Gulotta LV, Ehteshami JR, Warren RF, Rodeo SA. The effect of matrix metalloproteinase inhibition on tendon-to-bone healing in a rotator cuff repair model. J Shoulder Elb Surg. 2010;19:384–91.

    Article  Google Scholar 

  2. Demirag B, Sarisozen B, Ozer O, Kaplan T, Ozturk C. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg Am. 2005;87:2401–10.

    PubMed  Google Scholar 

  3. Scuderi GJ, Cuellar JM, Montesano PX. Intradiscal injection of autologous alpha-2-macroglobulin (A2M) concentrate alleviates back pain in FAC-positive patients. ISASS 2016, Abstract 202. http://www.isass.org/m/h/03_2029.html.

  4. Cawston TE, McLaughlin P, Hazleman BL. Paired serum and synovial fluid values of alpha 2-macroglobulin and TIMP in rheumatoid arthritis. Br J Rheumatol. 1987;26:354–8.

    Article  CAS  PubMed  Google Scholar 

  5. Ades EW, Hinson A, Chapuis-Cellier C, Arnaud P. Modulation of the immune response by plasma protease inhibitors. I. Alpha 2-macroglobulin and alpha 1-antitrypsin inhibit natural killing and antibody-dependent cell-mediated cytotoxicity. Scand J Immunol. 1982;15:109–13.

    Article  CAS  PubMed  Google Scholar 

  6. Fichter M, Körner U, Schömburg J, Jennings L, Cole AA, Mollenhauer J. Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytes. J Orthop Res. 2006;24:63–70.

    Article  CAS  PubMed  Google Scholar 

  7. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta. 1990;1052:366–78.

    Article  CAS  PubMed  Google Scholar 

  8. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322:547–9.

    Article  CAS  PubMed  Google Scholar 

  9. Goldring MB, Fukuo K, Birkhead JR, Dudek E, Sandell LJ. Transcriptional suppression by interleukin-1 and interferon-gamma of type II collagen gene expression in human chondrocytes. J Cell Biochem. 1994;54:85–99.

    Article  CAS  PubMed  Google Scholar 

  10. Stöve J, Huch K, Günther KP, Scharf HP. Interleukin-1beta induces different gene expression of stromelysin, aggrecan and tumor-necrosis-factor-stimulated gene 6 in human osteoarthritic chondrocytes in vitro. Pathobiology. 2000;68:144–9.

    Article  PubMed  Google Scholar 

  11. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434:644–8. Erratum in: Nature 2007;446:102

    Article  CAS  PubMed  Google Scholar 

  12. Rogerson FM, Chung YM, Deutscher ME, Last K, Fosang AJ. Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. Arthritis Rheum. 2010;62:3365–73.

    Article  CAS  PubMed  Google Scholar 

  13. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage. 2001;9:539–52. Erratum in: Osteoarthritis Cartilage 2002;10:82

    Article  CAS  PubMed  Google Scholar 

  14. Miller RE, Lu Y, Tortorella MD, Malfait AM. Genetically engineered mouse models reveal the importance of proteases as osteoarthritis drug targets. Curr Rheumatol Rep. 2013;15:350.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Homandberg GA, Wen C, Hui F. Cartilage damaging activities of fibronectin fragments derived from cartilage and synovial fluid. Osteoarthr Cartil. 1998;6:231–44.

    Article  CAS  PubMed  Google Scholar 

  16. Scuderi GJ, Woolf N, Dent K, Golish SR, Cuellar JM, Cuellar VG, et al. Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathology. Clin Biochem. 2010;43:808–14.

    Article  CAS  PubMed  Google Scholar 

  17. Scuderi GJ, Golish SR, Cook FF, Cuellar JM, Bowser RP, Hanna LS. Identification of a novel fibronectin-aggrecan complex in the synovial fluid of knees with painful meniscal injury. J Bone Joint Surg Am. 2011;93:336–40.

    Article  PubMed  Google Scholar 

  18. Scuderi GJ, Cuellar JM, Cuellar VG, Yeomans DC, Carragee EJ, Angst MS. Epidural interferon gamma-immunoreactivity: a biomarker for lumbar nerve root irritation. Spine (Phila Pa 1976). 2009;34:2311–7.

    Article  Google Scholar 

  19. Golish SR, Hanna LS, Bowser RP, Montesano PX, Carragee EJ, Scuderi GJ. Outcome of lumbar epidural steroid injection is predicted by assay of a complex of fibronectin and aggrecan from epidural lavage. Spine (Phila Pa 1976). 2011;36:1464–9.

    Article  Google Scholar 

  20. Meszaros E, Malemud CJ. Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity. Ther Adv Chronic Dis. 2012;3:219–29.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rothenberg ML, Nelson AR, Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells. 1999;17:237–40.

    Article  CAS  PubMed  Google Scholar 

  22. Amar S, Fields GB. Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12:445–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jotanovic Z, Mihelic R, Sestan B, Dembic Z. Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review. Drugs Aging. 2012;29:343–58.

    Article  CAS  PubMed  Google Scholar 

  24. Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q, et al. Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014;66:1843–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Jupiter Medical Center, Jupiter, FL, USA

    Gaetano J. Scuderi

  2. Cytonics Corporation, Jupiter, FL, USA

    Lewis Hanna

Authors
  1. Gaetano J. Scuderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lewis Hanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gaetano J. Scuderi .

Editor information

Editors and Affiliations

  1. Lenox Hill Hospital, New York, New York, USA

    Sudhir Diwan

  2. The Center for Pain Relief, Charleston, West Virginia, USA

    Timothy R Deer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Scuderi, G.J., Hanna, L. (2018). Alpha-2-Macroglobulin: Protease Inhibitor Treatment (PRP Variant). In: Diwan, S., Deer, T. (eds) Advanced Procedures for Pain Management. Springer, Cham. https://doi.org/10.1007/978-3-319-68841-1_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68841-1_39

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68839-8

  • Online ISBN: 978-3-319-68841-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation